- Previous Close
0.7680 - Open
0.8335 - Bid 0.5951 x 100
- Ask 1.0400 x 100
- Day's Range
0.7990 - 0.8700 - 52 Week Range
0.6300 - 6.8000 - Volume
170,475 - Avg. Volume
239,610 - Market Cap (intraday)
44.73M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6800 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.33
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
preludetx.comRecent News: PRLD
View More
Performance Overview: PRLD
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRLD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRLD
View MoreValuation Measures
Market Cap
42.47M
Enterprise Value
-73.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.34
Price/Book (mrq)
0.32
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.54%
Return on Equity (ttm)
-69.01%
Revenue (ttm)
7M
Net Income Avi to Common (ttm)
-127.17M
Diluted EPS (ttm)
-1.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
133.61M
Total Debt/Equity (mrq)
13.71%
Levered Free Cash Flow (ttm)
-62M
Research Analysis: PRLD
View MoreResearch Reports: PRLD
View MoreDaily – Vickers Top Insider Picks for 04/01/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/31/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Buyers & Sellers for 03/28/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 03/28/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.